» Articles » PMID: 7882171

CTLA-4 Can Function As a Negative Regulator of T Cell Activation

Overview
Journal Immunity
Publisher Cell Press
Date 1994 Aug 1
PMID 7882171
Citations 696
Authors
Affiliations
Soon will be listed here.
Abstract

CD28 and CTLA-4 are related glycoproteins found on T cells. Ligation of CD28 following antigen receptor engagement provides a costimulatory signal required for T cell activation. Anti-CTLA-4 antibodies were generated to examine the role of the CTLA-4 receptor on murine T cells. Expression of CTLA-4 as a homodimer is up-regulated 2-3 days following T cell activation. Anti-CTLA-4 antibodies and Fab fragments augmented T cell proliferation in an allogeneic MLR. However, when optimal costimulation and Fc cross-linking were present, anti-CTLA-4 Mabs inhibited T cell proliferation. Together, these results suggest that the MAb may obstruct the interaction of CTLA-4 with its natural ligand and block a negative signal, or directly signal T cells to down-regulate immune function.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.


Immunological Landscape of Non-Melanoma Skin Neoplasms: Role of CTLA4+IFN-γ+ Lymphocytes in Tumor Microenvironment Suppression.

Karabatic Knezovic S, Knezovic D, Ban J, Matana A, Puizina Ivic N, Glavina Durdov M Medicina (Kaunas). 2025; 61(2).

PMID: 40005446 PMC: 11857809. DOI: 10.3390/medicina61020330.


Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy.

Abdo E, Ajib I, El Mounzer J, Husseini M, Kalaoun G, Matta T Inflamm Res. 2025; 74(1):41.

PMID: 39960501 DOI: 10.1007/s00011-025-02008-5.


It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma.

Knickmeier C, Noubissi Nzeteu G, Gibbs B, Hoogwater F, Nijkamp M, Bockhorn M Front Immunol. 2025; 16:1495907.

PMID: 39958335 PMC: 11825744. DOI: 10.3389/fimmu.2025.1495907.


Immune checkpoint inhibitors: Utilizing patient's own immunity to treat oral cancer.

Phulari R, Solanki B J Oral Maxillofac Pathol. 2025; 28(4):641-650.

PMID: 39949682 PMC: 11819625. DOI: 10.4103/jomfp.jomfp_327_22.